Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson’s Disease

FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson’s disease

See more here